ERBB2 and cancer: In contrast to KLH–GP2, sera from mice immunized with vaccine construct that bears an additional B-cell epitope (KLH–GP2–P4) elicited a significantly higher titer of antigen-specific antibodies, which resulted in a greater neutralizing effect against TUBO cancer cells (murine HER2-positive cell line).